Comparative Pharmacology
Head-to-head clinical analysis: OGESTREL 0 5 50 21 versus SYEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGESTREL 0 5 50 21 versus SYEDA.
OGESTREL 0.5/50-21 vs SYEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive